Capital Markets

MUFG puts ‘boots on the ground’ in Canada capital markets bid

Mitsubishi UFJ Financial Group is looking to build a capital-markets platform in Canada, with plans to hire as many as 10 people in Toronto to manage bond deals and stock sales by early next year.It’s a significant shift for a Japanese bank that’s kept a low profile in the country for decades.“It’s a natural extension of our business as a ...

Read More »

Intercept Pharmaceuticals, Inc. (ICPT) Price Target Lowered to $160.00 at BMO Capital Markets

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) had its target price decreased by BMO Capital Markets from $221.00 to $160.00 in a research note published on Friday morning. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock. ICPT has been the subject of several other reports. Cantor Fitzgerald restated an underweight rating and set a $69.00 price target (up ...

Read More »

Pro-Dex’s (PDEX) “Buy” Rating Reiterated at Ascendiant Capital Markets

Ascendiant Capital Markets reissued their buy rating on shares of Pro-Dex, Inc. (NASDAQ:PDEX) in a report released on Friday, September 8th. Ascendiant Capital Markets currently has a $9.00 price target on the medical instruments supplier’s stock, up from their prior price target of $8.00. Pro-Dex (NASDAQ PDEX) traded down 1.32% on Friday, hitting $7.50. The stock had a trading volume ...

Read More »

Union Pacific Corporation’s (UNP) “Buy” Rating Reiterated at BMO Capital Markets

BMO Capital Markets reaffirmed their buy rating on shares of Union Pacific Corporation (NYSE:UNP) in a research report sent to investors on Friday, September 15th. BMO Capital Markets currently has a $123.00 price target on the railroad operator’s stock. A number of other brokerages also recently issued reports on UNP. Royal Bank Of Canada reaffirmed a hold rating and issued ...

Read More »

BioMarin Pharmaceutical’s (BMRN) Buy Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets reaffirmed their buy rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in a research report sent to investors on Friday, September 15th. Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies started coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued an overweight rating and a $113.00 price ...

Read More »

Five Prime Therapeutics, Inc. (FPRX) Receives Hold Rating from BMO Capital Markets

BMO Capital Markets reiterated their hold rating on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in a research report sent to investors on Friday morning. BMO Capital Markets currently has a $39.00 target price on the biotechnology company’s stock. A number of other equities analysts have also commented on the stock. Royal Bank Of Canada started coverage on shares of ...

Read More »

BMO Capital Markets Reiterates “Hold” Rating for eBay Inc. (NASDAQ:EBAY)

BMO Capital Markets reissued their hold rating on shares of eBay Inc. (NASDAQ:EBAY) in a research report report published on Wednesday, September 13th. Other equities analysts also recently issued research reports about the company. Goldman Sachs Group, Inc. (The) set a $42.00 price target on eBay and gave the stock a buy rating in a research report on Wednesday, June ...

Read More »

Interpublic Group of Companies, Inc. (The) (NYSE:IPG) Stock Rating Reaffirmed by BMO Capital Markets

BMO Capital Markets reaffirmed their buy rating on shares of Interpublic Group of Companies, Inc. (The) (NYSE:IPG) in a research report sent to investors on Wednesday, September 13th. BMO Capital Markets currently has a $26.00 target price on the business services provider’s stock. Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Interpublic ...

Read More »

Jazz Pharmaceuticals PLC (JAZZ) Earns Buy Rating from BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report published on Wednesday morning. The firm currently has a $196.00 target price on the specialty pharmaceutical company’s stock. Other analysts have also issued reports about the stock. Leerink Swann boosted their price objective on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 ...

Read More »